EUVIMEDOpdag EUVIMED
Crossref

Integrative Molecular Scaffold Generation of PI3K/mTOR Inhibitors Using DeepSARM and Ligand‐Based Virtual Screening Approaches

Kenichiro Shimokawa iD, Yumi N Imai, Yasuyoshi Arikawa, Jianwei Liu, Yiming Wu, Mitsuyo Kondo, Atsushi Yoshimori iD

ChemMedChem · 2026-07-14 · 21 (13)

DOI: 10.1002/cmdc.70362 ↗

At a glance

Journal article in ChemMedChem, published online on 2026-07-08. Written by Kenichiro Shimokawa and 6 co-authors. Institution: Chordia Therapeutics Inc., Fujisawa, Kanagawa, Japan. Major MEDLINE topics: TOR Serine-Threonine Kinases, Phosphoinositide-3 Kinase Inhibitors, Protein Kinase Inhibitors, MTOR Inhibitors. 30 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Designing novel core scaffolds for small molecules is an important yet challenging task in medicinal chemistry, particularly during the lead‐generation stage and in situations that require alternative chemotypes and/or chemical novelty. In this study, we applied an artificial intelligence‐based structure generation using the DeepSARM methodology to create novel scaffold series and to augment medicinal chemistry capabilities. Samotolisib, a PI3K/mTOR dual inhibitor featuring a tricyclic scaffold, was selected as a model ligand. Following DeepSARM‐guided structure generation and ligand‐based virtual screening, several candidate compounds with simplified scaffolds were identified. Notably, one top‐ranked virtual hit 6 was selected and further optimized into a simplified tool compound 6A for experimental validation. Subsequent synthesis and in vitro evaluation led to the identification of a validated hit bearing a novel nontricyclic scaffold.

Subjects

MeSH terms (MEDLINE)

TOR Serine-Threonine KinasesPhosphoinositide-3 Kinase InhibitorsProtein Kinase InhibitorsMTOR InhibitorsLigandsPhosphatidylinositol 3-KinasesHumansStructure-Activity RelationshipMolecular StructurePharmacophoreDrug Evaluation, PreclinicalDose-Response Relationship, DrugMolecular Docking Simulation

Author keywords

DeepSARMPI3K/mTOR inhibitorsligand‐based virtual screeningpharmacophore modelscaffold generation

Substances

LigandsTOR Serine-Threonine KinasesPhosphoinositide-3 Kinase InhibitorsPhosphatidylinositol 3-KinasesProtein Kinase InhibitorsMTOR InhibitorsMTOR protein, human

Authors and institutions

  • Chordia Therapeutics Inc., Fujisawa, Kanagawa, Japan.
  • WuXi AppTec Co. Ltd., Shanghai, P. R. China.
  • Axcelead Drug Discovery Partners Inc., Fujisawa, Kanagawa, Japan.
  • Institute for Theoretical Medicine Inc., Fujisawa, Kanagawa, Japan.

ORCID profiles: Kenichiro Shimokawa, Atsushi Yoshimori

Cite

APA

Shimokawa, K., Imai, Y. N., Arikawa, Y., Liu, J., Wu, Y., Kondo, M., & Yoshimori, A. (2026). Integrative Molecular Scaffold Generation of PI3K/mTOR Inhibitors Using DeepSARM and Ligand‐Based Virtual Screening Approaches. ChemMedChem, 21(13). https://doi.org/10.1002/cmdc.70362

Vancouver

Shimokawa K, Imai YN, Arikawa Y, Liu J, Wu Y, Kondo M, et al. Integrative Molecular Scaffold Generation of PI3K/mTOR Inhibitors Using DeepSARM and Ligand‐Based Virtual Screening Approaches. ChemMedChem. 2026;21(13). doi:10.1002/cmdc.70362

BibTeX
@article{Shimokawa2026,
  author = {Shimokawa, Kenichiro and Imai, Yumi N and Arikawa, Yasuyoshi and Liu, Jianwei and Wu, Yiming and Kondo, Mitsuyo and Yoshimori, Atsushi},
  title = {Integrative Molecular Scaffold Generation of PI3K/mTOR Inhibitors Using DeepSARM and Ligand‐Based Virtual Screening Approaches},
  journal = {ChemMedChem},
  year = {2026},
  volume = {21},
  number = {13},
  doi = {10.1002/cmdc.70362}
}
Start for free →